News

Public · Published

Guggenheim maintains Faeth Therapeutics at Buy, lowers price target to $69 from $70

Guggenheim kept its Buy rating on Faeth Therapeutics but lowered its price target, an analyst's estimate of a possible future share price, to $69 from $70. The revised target is 1.4% lower and implies 251.1% upside from the November 3 closing price of $19.65.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Faeth Therapeutics but lowered its price target, an analyst’s estimate of a possible future share price, to $69 from $70. The revised target is 1.4% lower and implies 251.1% upside from the November 3 closing price of $19.65.

Confirmed

Global impact / market context

The unchanged Buy rating signals that Guggenheim remains positive, while the lower target slightly reduces its estimate of potential share-price gains. Analyst targets can shape investor expectations and positioning, but they are opinions rather than company results and do not guarantee future performance.

Analyst inference

The supplied information describes one analyst’s rating and target revision, not a change in Faeth’s reported operations, finances, or business outlook. The stated upside compares the target with the November 3 close; it does not establish that the shares will reach that level.

Analyst inference

What to watch

  1. Watch for any later Guggenheim update to the Buy rating or $69 target, since a further revision would change this analyst’s stated view of potential share value. Analyst inference
  2. Look for company updates on operating results or business plans; the supplied report provides no new company information that explains the target reduction. Analyst inference
  3. Compare future analyst targets with Faeth’s reported results and share price to assess whether expectations are changing alongside company performance. Analyst inference

Evidence

  • Original source link unavailable